Parkinson’s Disease and Movement Disorders Clinic, the Sagol Neuroscience Center, Department of Neurology, Israel.
Neurology. 2012 Mar 13;78(11):781-6. doi: 10.1212/WNL.0b013e318249f673. Epub 2012 Feb 8.
In view of the fact that cancer patterns in patients with Parkinson disease (PD) differ from the general population, we aimed to verify whether patients with PD with LRRK2 mutations have an increased risk for particular cancer types.
In this cross-sectional study, eligible consenting Jewish patients with PD were genotyped for the predominant LRRK2 G2019S mutation. Oncologic data were obtained by personal interview and reviewing patients' files. Stepwise logistic regression was applied to model the probability of cancer occurrence in carriers vs noncarriers.
Overall, 79/490 (16.1%) genotyped patients carried the G2019S mutation. Seventy-seven (16%) were diagnosed with cancer; of those, 67 (14%) with a non-skin cancer. Eighteen (23%) carriers vs 49 (12%) noncarriers had a non-skin cancer (p = 0.01, odds ratio [OR] = 2.18, 95% confidence interval [CI] 1.19-3.99). A significant ethnicity effect was noted (p = 0.045, OR = 1.84, 95% CI 1.02-3.34). Among Ashkenazi patients, age and LRRK2 emerged as significant using stepwise logistic regression including age, gender, and LRRK2 status as explanatory variables. The OR for LRRK2 mutation carriers adjusted for age was 3.38 (95% CI 1.64-6.97, p = 0.0009).
Ashkenazi Jewish patients with PD who harbor the G2019S LRRK2 mutation are more likely to have a concomitant non-skin cancer than noncarriers.
鉴于帕金森病（PD）患者的癌症模式与一般人群不同，我们旨在验证携带 LRRK2 突变的 PD 患者是否存在特定癌症类型的风险增加。
在这项横断面研究中，合格的同意参加的犹太 PD 患者被进行主要的 LRRK2 G2019S 突变基因分型。通过个人访谈和查阅患者档案获得肿瘤学数据。逐步逻辑回归用于建立携带者与非携带者发生癌症的概率模型。
总体而言，490 名基因分型患者中有 79 名（16.1%）携带 G2019S 突变。77 名（16%）被诊断患有癌症；其中 67 名（14%）患有非皮肤癌。18 名（23%）携带者与 49 名（12%）非携带者患有非皮肤癌（p = 0.01，优势比[OR] = 2.18，95%置信区间[CI] 1.19-3.99）。注意到显著的种族效应（p = 0.045，OR = 1.84，95% CI 1.02-3.34）。在阿什肯纳兹患者中，年龄和 LRRK2 成为显著因素，使用逐步逻辑回归，包括年龄、性别和 LRRK2 状态作为解释变量。校正年龄后 LRRK2 突变携带者的 OR 为 3.38（95% CI 1.64-6.97，p = 0.0009）。
携带 G2019S LRRK2 突变的阿什肯纳兹犹太 PD 患者比非携带者更有可能同时患有非皮肤癌。
